STRO Sutro Biopharma Inc
Price (delayed)
$0.6304
Market cap
$52.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.96
Enterprise value
-$115.2M
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Highlights
The company's debt fell by 31% YoY and by 7% QoQ
STRO's net income has plunged by 113% YoY and by 84% from the previous quarter
STRO's EPS has plunged by 84% from the previous quarter and by 66% YoY
Key stats
What are the main financial stats of STRO
Market
Valuations
Earnings
Shares outstanding
83.78M
Market cap
$52.81M
Enterprise value
-$115.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.17
Price to sales (P/S)
0.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.86
Revenue
$62.04M
Gross profit
$62.04M
Operating income
-$238.45M
Net income
-$227.46M
EBIT
-$199.32M
EBITDA
-$186.96M
Free cash flow
-$194.64M
Per share
Balance sheet
Liquidity
EPS
-$2.96
EPS diluted
-$2.96
Free cash flow per share
-$2.53
Book value per share
$0.54
Revenue per share
$0.81
TBVPS
$5.04
Total assets
$387.21M
Total liabilities
$342.61M
Debt
$23.15M
Equity
$44.6M
Working capital
$211.42M
Debt to equity
0.52
Current ratio
2.6
Quick ratio
2.47
Net debt/EBITDA
0.9
Margins
Efficiency
Dividend
EBITDA margin
-301.3%
Gross margin
100%
Net margin
-366.6%
Operating margin
-384.3%
Return on assets
-52.5%
Return on equity
-224.1%
Return on invested capital
-95.2%
Return on capital employed
-78.1%
Return on sales
-321.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
STRO stock price
How has the Sutro Biopharma stock price performed over time
Intraday
5.9%
1 week
-17.64%
1 month
-60.35%
1 year
-87.61%
YTD
-65.74%
QTD
-3.1%
Financial performance
How have Sutro Biopharma's revenue and profit performed over time
Revenue
$62.04M
Gross profit
$62.04M
Operating income
-$238.45M
Net income
-$227.46M
Gross margin
100%
Net margin
-366.6%
STRO's operating income has dropped by 167% year-on-year and by 83% since the previous quarter
STRO's net income has plunged by 113% YoY and by 84% from the previous quarter
Sutro Biopharma's revenue has shrunk by 61% QoQ and by 60% YoY
The gross profit has plunged by 61% from the previous quarter and by 60% YoY
Growth
What is Sutro Biopharma's growth rate over time
Valuation
What is Sutro Biopharma stock price valuation
P/E
N/A
P/B
1.17
P/S
0.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.86
STRO's EPS has plunged by 84% from the previous quarter and by 66% YoY
The equity has dropped by 70% year-on-year and by 60% since the previous quarter
The stock's price to book (P/B) is 61% less than its last 4 quarters average of 2.8 and 50% less than its 5-year quarterly average of 2.2
The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 7.0 and 61% less than its last 4 quarters average of 1.9
Sutro Biopharma's revenue has shrunk by 61% QoQ and by 60% YoY
Efficiency
How efficient is Sutro Biopharma business performance
STRO's return on invested capital has dropped by 172% year-on-year
Sutro Biopharma's ROE has plunged by 131% from the previous quarter
STRO's return on assets has dropped by 112% year-on-year and by 92% since the previous quarter
Dividends
What is STRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for STRO.
Financial health
How did Sutro Biopharma financials performed over time
STRO's total assets is 13% greater than its total liabilities
The quick ratio has contracted by 44% YoY and by 18% from the previous quarter
Sutro Biopharma's current ratio has decreased by 42% YoY and by 16% from the previous quarter
The company's debt is 48% lower than its equity
Sutro Biopharma's debt to equity has soared by 136% from the previous quarter and by 136% YoY
The equity has dropped by 70% year-on-year and by 60% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.